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Abstract
Disease progression in HIV-infected individuals varies greatly, and while the environmental and host factors influencing this
variation have been widely investigated, the viral contribution to variation in set-point viral load, a predictor of disease
progression, is less clear. Previous studies, using transmission-pairs and analysis of phylogenetic signal in small numbers of
individuals, have produced a wide range of viral genetic effect estimates. Here we present a novel application of a
population-scale method based in quantitative genetics to estimate the viral genetic effect on set-point viral load in the UK
subtype B HIV-1 epidemic, based on a very large data set. Analyzing the initial viral load and associated pol sequence, both
taken before anti-retroviral therapy, of 8,483 patients, we estimate the proportion of variance in viral load explained by viral
genetic effects to be 5.7% (CI 2.8–8.6%). We also estimated the change in viral load over time due to selection on the virus
and environmental effects to be a decline of 0.05 log10 copies/mL/year, in contrast to recent studies which suggested a
reported small increase in viral load over the last 20 years might be due to evolutionary changes in the virus. Our results
suggest that in the UK epidemic, subtype B has a small but significant viral genetic effect on viral load. By allowing the
analysis of large sample sizes, we expect our approach to be applicable to the estimation of the genetic contribution to
traits in many organisms.
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Introduction
Plasma viral load has long been considered one of the most
important clinical measures in HIV-positive patients. The
progression time from infection to AIDS or death varies
enormously from a few years to decades, and ‘set-point’ viral
load, taken early in the asymptomatic phase of the disease, is the
best known early predictor of the long-term rate of disease
progression [1–3] and is also strongly associated with transmission
risk [4–6]. Variation in host genes, particularly HLA [7–12] but
also the CCR5 co-receptor and its ligands, and even the gene
APOBEC3G [13–15], has been identified as influencing progres-
sion rate, but the contribution of the viral genome is still much less
clear.
Nevertheless, the hypothesis that HIV could be evolving to
become more virulent has been a driver for decades of HIV
research. In the mid-1980’s, it became clear that some HIV
isolates, deemed ‘high/fast’ lines, had a much higher replicative
capacity in cell lines than others [16–18]. When a drop in CD4+
cell count at diagnosis was reported a few years later [19,20],
speculation began as to whether the spread of these ‘high/fast’
lines could be responsible [20–22]. A number of studies looking at
long-term trends in HIV virulence were published, drawing mixed
conclusions on whether there was evidence of HIV becoming
more virulent [23–35]. However, a lack of standardization of when
measurements were taken, what measures were used, and whether
patients were on anti-retroviral therapy (ART), as well as
differences in the subtypes, risk groups, and demographics of the
patients involved mean that these studies are difficult to compare
directly. Despite this, two meta-analyses have been performed,
both concluding that a decrease in CD4+ count and an increase in
viral load can be observed, implying an increase in HIV virulence
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that both papers suggest could be caused by viral factors [36,37].
This would require that the viral genome exerted some influence
over the set-point viral load. In the context of drug resistance it is
well known that viral variation affects the replication capacity of
HIV (reviewed in [38]), suggesting that such a viral genetic
influence could indeed be possible.
Evolutionary theory predicts that pathogens evolve to modulate
their density within hosts in order to maximize transmission rate.
In the classic studies of myxomatosis [39], viral genotypes with
reduced replication rates that permitted longer host survival were
selected for when host density, and thus transmission probability,
declined as the epidemic progressed. This, along with classic
studies on the link between transmission and virulence [40,41],
raises the possibility that in the 100 years HIV is known to have
infected humans [42,43], it might have adapted to different levels
of transmission probability associated with different infected
populations [2,6]. Studies of disease progression and viral load
have found evidence of differences between HIV-1 subtypes [44–
46], suggesting that major viral genetic differences among
immunodeficiency viruses influence virulence.
Three studies investigated the contribution of viral genotype to
set-point in studies of HIV sero-discordant couples. In these studies
of 115, 56, and 47 sequence verified transmission-pairs in Zambia,
the Netherlands and the USA, correlation coefficients of 0.21, 0.25,
and 0.55, respectively, were estimated between set-point viral load
in the index and contact cases [10,47,48]. Another transmission-
pair study on 28 couples from Uganda reported the coefficient of
determination from ANOVA analysis as R2 = 27%, and R2 = 37%
after adjusting for confounding effects [49]. In a fourth study, based
on the Swiss Cohort, Alizon et al. [50] adopted a phylogenetic
approach, looking for a signal of inherited viral effect in men who
have sex with men (MSM) infected with subtype B. Phylogenetic
signal measures the amount that the connections in a phylogeny
explain the similarity in trait values seen in different individuals
[51,52]. Using their strictest definition of set-point viral load and
consequently their smallest sample size (n = 134), Alizon et al. [50]
obtained a statistically significant estimate that approximately half of
the variation observed in viral load could be explained by viral
genetic effects. However, the estimates obtained using a more liberal
definition of set-point viral load in the MSM group (n = 404) were
much lower, at around 11%, and in the largest datasets where all
risk-groups were included the estimates were non-significant.
Given the small numbers in all of these studies, we sought an
alternative approach which would allow the inclusion of the large
numbers of individuals for which both plasma viral load and viral
sequence data are now available.
In quantitative genetics the proportion of the total trait variation
(VP) caused by additive genetic factors (VA) is described as its narrow-
sense heritability (h2). Numerous approaches have been proposed to
estimate variance components and heritability from phylogenetic
data, including restricted maximum-likelihood (REML) [53],
maximum-likelihood (ML) [51], and generalized least squares
[52]. REML methods have emerged as the preferred choice for
variance component and heritability estimation due to their ability
to give unbiased estimates [54–56]. In 1996 the program ASReml
introduced an efficient implementation of REML-based variance
estimation specifically designed for data from pedigreed individuals
[56,57]. By measuring the relationships between individuals on the
pedigree as the probability that their alleles are identical by descent,
and linking this to the observed differences in trait measures, the
amount of trait variation explained by the genetic relationships can
be estimated. These identical by descent relationship measures are
calculated from the pedigree to form a genetic relatedness matrix,
usually referred to as A [58].
For a phylogeny, the phylogenetic covariance of two taxa is
proportional to the total length from the taxa’s most recent
common ancestor (MRCA) to the root under a Brownian motion
model of evolution [59,60], and the covariances between all taxa
can be represented by the matrix A. In order to calculate variance
components the inverse of A, A21, is usually needed, but can be
computationally resource intensive to calculate [56,58]. Hender-
son [58] showed that for pedigrees this problem can be made
easier by including ‘phantom parents’ for all individuals with
unknown parentage so that the population could be traced back to
unrelated ancestors. Hadfield and Nakagawa [56] extended this
technique to phylogenies by expanding A to include all the internal
nodes in the tree, allowing the inverse matrix to be calculated by
the method of Henderson [58] and to provide a structure to the
model that can be exploited by generic sparse matrix algorithms
[61]. (See [62] for an alternative algorithm.)
Here, we apply this approach by using ASReml to estimate the
heritability of viral load in the UK subtype B HIV epidemic,
analyzing set-point viral load in almost 8,500 individuals for whom
matched HIV sequences and viral load data were available.
Results
The sequences used were made available by the UK HIV Drug
Resistance Database (UK HIV RDB), which collects pol sequences
from HIV-positive patients attending clinics across the UK before
starting and during ART in order to detect resistance mutations.
The UK HIV RDB was estimated to contain sequences for
approximately two-thirds of the subtype B MSM patients who
were treated for HIV in the UK in 2006 [63]. The first sequence
available for each patient was analyzed. Fully anonymized clinical
data corresponding to many of the sequences was made available
by the UK Clinical HIV Cohort (UK CHIC) [64], with viral load
before starting ART being available for 8,700 initial subtype B
sequences, reflecting the most prevalent subtype epidemic in the
UK. The data used were the most current available, with
sequences and clinical data collected up to mid-2009.
After removing all cases where there was uncertainty over
disease or treatment status or large sections of sequence were
missing, 8,483 subtype B sequences and associated viral load
measurements remained. The demographics of the dataset show
that 73% (6,198 individuals) were white MSM, reflecting the
historic preponderance of this subtype among MSM (Table 1). A
phylogeny of these sequences was generated using RAxML
[65,66] with 38 subtype reference pol sequences from the Los
Alamos HIV Database (www.hiv.lanl.gov) used as an outgroup.
Author Summary
HIV viral load, the amount of virus in the blood, is an
important predictor of rate of CD4+ cell decline, time to
AIDS and onwards transmission. Plasma viral load is
influenced by many environmental and host factors, but
the contribution of the viral genome is not yet clear. We
have adapted a method from quantitative genetics which
considers the viral phylogeny as a pedigree, permitting
analysis of large cohort-derived datasets for the first time.
We found the viral genome contributes significantly to the
level of the set point viral load, but only determines about
6% of the variation in this property in this population. Our
study also suggests that the change over time in mean
plasma viral load described in some recent studies has not
been due to a change in the component of viral load that
is contributed by viral genotype.
Heritability of Set-Point Viral Load in HIV
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Preliminary runs in ASReml were used to determine the fixed
and random effects for the model. Sex, ethnicity, country of origin,
age when the set-point viral load was taken, year of HIV diagnosis,
and time from HIV diagnosis to the date when set-point viral load
was taken, were all included in the final model (effect estimates
given in Table S1). Set-point viral load was found to increase with
age, but decrease with a more recent year of diagnosis and with a
longer time period between HIV diagnosis and viral load testing.
HIV-positive females and non-white individuals were found to
have decreased set-point viral load measures compared to males
and white individuals. The random effects were estimated to have
a variance of 3.1161023 and 6.5561024 for year of HIV
diagnosis and country of origin, respectively.
To confirm that our method performed as expected when tested
on trees with known heritabilities we performed a simulation
analysis similar to that of Alizon et al. [50]. We found the
estimated heritability values to correspond well with the simulated
values (see Text S1).
Bootstrapped phylogenetic trees were reconstructed in duplicate
on the 8,483 sequences and both trees analyzed using ASReml
independently. Using the comparison of the resulting log-
likelihood values from running the model with and without the
tree to estimate significance, both replicates produced highly
significant (p,0.0001) heritability estimates of 5.8% (CI 2.9–8.7%)
and 5.6% (CI 2.6–8.5%; Table 2).
As is typical for phylogenies based on population samples of
HIV pol sequences, there is relatively little well-supported internal
structure. In order to avoid possible bias in the heritability
estimates, the analysis was repeated after splits with bootstrap-
support values less than 90% were collapsed (Fig. S1), which
removed 78% of internal nodes. Nevertheless, the heritability
estimates remained significant in each case, with estimates of 5.1%
(CI 2.4–7.8%) and 6.0% (CI 3.1–8.8%). However, when the entire
tree was collapsed (excepting the split to the outgroup) leaving only
branch-length information, the estimate was not significant,
highlighting that detecting the heritability signal relies on at least
some tree structure. One hundred bootstrapped phylogenies were
analyzed to further examine the effect of uncertainty in the tree.
Only four of the resulting heritability estimates failed to reach
significance after Bonferroni correction (though their p-values
were still,0.002), resulting in a mean heritability estimate of 5.5%
(CI 2.6–8.5%) (data not shown).
In order to investigate how the viral genetic effect on set-point
viral load varies across the phylogeny and through time, we
constructed a time-resolved phylogeny using BEAST [67]. For
reasons of computational tractability, this phylogeny had to be
generated on a 652-sequence sub-sample of the dataset but
produced a significant heritability estimate of 5.1% (upper CI
11.2%, p,0.005). We then used ASReml to estimate the
phylogenetic effect of each node on viral load and mapped these
estimates onto the time-resolved phylogeny, allowing the distribu-
tion of the effects across the tree and over time to be visualized.
This showed some viral lineages to be clearly associated with
substantial positive genetic effects on viral load, relative to the
mean, and others to be associated with equally large negative
effects (Fig. 1).
To investigate more formally the change in set-point viral load
over time, we conducted an analysis in the R package
MCMCglmm [68,69] in order to estimate the change in viral
load due to selection on the virus and environmental effects using
information from the temporal variation in sample dates (see Text
S2). Analysis of the change due to selection on the virus and
environmental effects revealed that this would have contributed a
small but significant negative change in viral load of 20.05 log10
copies/mL/year (Fig. 2).
Discussion
Our analysis showed that viral genotype has a small but
significant effect on set-point viral load in this population, with an
estimated mean heritability of 5.7% (CI 2.8–8.6%). When the
analysis was repeated after subsampling and using a different
phylogenetic method, the heritability remained significant and did
not differ significantly from the original estimate. As the star-like
Table 1. Demographics of patients whose samples were
analyzed.
Subtype B (n=8,483)
Age at Set-point (years) (mean, range): 35.4 (15–83)
Log10 Set-point Viral Load (mean, SD): 4.49360.86
Sex Female: 464 (5.5%)
Male: 8019 (94.5%)
Risk Group Homo/Bisexual: 7278 (85.8%)
Heterosexual: 711 (8.4%)
IDU: 239 (2.8%)
Other/Unknown: 255 (3.0%)
Ethnicity White: 6990 (82.4%)
Black: 597 (7.0%)
Asian: 221 (2.6%)
Other/Unknown: 675 (8.0%)
doi:10.1371/journal.ppat.1004112.t001
Table 2. Estimates of viral genetic influence on set-point viral load in HIV subtype B in the UK.
Dataset Method N Replicate Viral Heritability (Conf. Interval)
Full dataset RAxML 8,483 1 5.8% (2.9–8.7%)
2 5.6% (2.6–8.5%)
Nodes with bootstraps ,90% collapsed RAxML 8,483 1 5.1% (2.4–7.8%)
2 6.0% (3.1–8.8%)
BEAST 652 Sub-Sample BEAST 652 1 5.1% (0–11.2%)
1,726 sequences with only 1 viral load removed RAxML 6,757 1 7.8% (4.3–11.3%)
2 6.6% 3.4–9.9%)
doi:10.1371/journal.ppat.1004112.t002
Heritability of Set-Point Viral Load in HIV
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structure of HIV phylogenies can cause poor resolution of the
internal nodes, resulting in low split support values, the impact of
this effect was tested by collapsing weakly-supported nodes and
analyzing one hundred bootstrapped phylogenies. This showed
that the heritability estimates and their significance were not due
to spurious or poorly-supported splits. Finally, a simulation
analysis following the method of Alizon et al. [50] confirmed that
our method of estimating heritability down a phylogeny performed
as expected on a phylogeny where heritability is known (Text S1).
Analyzing smaller sampled datasets in BEAST allowed further
investigation of the genetic effect on viral load. Plotting the
estimated node effect on viral load back onto the phylogeny for the
652 sampled sequences illustrates the association of closely related
sequences and similar genetic effects on viral loads in transmission
chains that seem to have begun differentiating around the time
subtype B arrived in the UK [70]. Finding viral lineages with both
positive and negative genetic effects on viral load indicates that
there is viral genetic variation that acts to both increase and
decrease viral load relative to the mean.
Our estimates of the fixed effects influencing set-point viral load
reflect previous reports identifying age [71,72] and sex [73–75] as
significant, with older individuals and males having higher set-
point viral loads. We also found ethnicity to have a significant
effect on set-point viral load, finding a similar estimate for the
effect of Black-African ethnicity to a previous paper looking
specifically at this effect [76]. Although many previous studies on
the influence of ethnicity on set-point viral load suggest there is no
difference between ethnic groups or that non-white minorities
have higher viral loads [77–79], differences in socio-economic
status, risk-group, and access to care make the effect of ethnicity
difficult to investigate [79]. Our finding that those with a longer
time from HIV diagnosis to viral load testing had a slightly lower
set-point viral load could reflect that individuals with lower viral
load progress more slowly and therefore may be in general slower
to access care, and also indicates that we are not classifying late-
stage, rising viral loads as ‘set-point,’ which would result in the
opposite effect. Finally, the fact that individuals with a more recent
year of diagnosis also have a slightly lower set-point viral load
could suggest that the proportion of individuals being diagnosed in
late-stage infection is decreasing with time [80].
Previous studies investigating the heritability of viral load in
HIV have estimated the genetic effect at between 11 to 60%,
higher than the estimate of 5.7% obtained here. Three of the five
studies were done on cohorts infected with subtypes other than B;
one on subtype C [10] and two on mixed subtype populations
[47,49], making comparisons difficult. Because virulence differs
between subtypes [44–46], heritability estimates could be affected
in studies where the cohort is infected with multiple subtypes, even
when subtype is included as a variable in the model. Similarly,
both the environmental and genetic variance that determines
heritability can vary between populations, and may be particularly
divergent between studies focusing on different demographic or
risk groups (see [81] for further discussion). Considering this, some
disparity in heritability estimates may not be unexpected.
Four of the previous studies used transmission pairs (n = 28 to
n = 115) to estimate the heritability of viral load, and this could
also influence the estimates obtained. As pointed out in one of
these studies [10], the sero-discordant couples where transmission
does occur may not accurately reflect the epidemic as a whole. As
viral load is proportional to the probability of transmission,
partners who transmit HIV and thus get included in the analysis
had higher viral loads than average for the study [10]. Cohabiting
or long-term sexual partners may also share confounded
environmental factors such as diet and exposure to other
Figure 1. The estimated node effect plotted onto the
phylogeny. The estimated phylogenetic effect of each node on
log10 viral load plotted back onto the phylogeny from the 652-sample
BEAST analysis. The axis shows the time in years from the most recent
sequence, which was taken in 2009. Branches have been colored by the
scale of the effect. Clusters of branches have been collapsed to improve
readability, and are colored by the average tip effect within each
cluster. As the number of bifurcations in the tree reduces at around 17.5
years before 2009, this used as the threshold for collapsing. Nodes that
have a similar effect on viral load cluster together, as expected if some
of the variation in viral load is heritable.
doi:10.1371/journal.ppat.1004112.g001
Figure 2. Change in viral load over time due to selection. The
estimated log10 change in viral load per year due to selection and
environmental effects (see also Fig. S2).
doi:10.1371/journal.ppat.1004112.g002
Heritability of Set-Point Viral Load in HIV
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pathogens, which could affect health and thus viral load, and may
even share HLA alleles, which increases HIV transmission risk and
the between-partner correlation in viral load [82,83].
The only previous study that utilized a phylogeny-based
approach also reported a heritability estimate considerably higher
than the one obtained here. Alizon et al. [50] obtained a
significant heritability estimate of around 50% when they used the
most stringent criteria to define which samples would be taken as
set-point viral load. Heritability estimates apply only to the
population studied, so their estimate may be specific to this small
(n = 134) population of MSM individuals with exceptionally stable
viral load measures. Interestingly, when they relaxed their
definition of set-point viral load, tripling the sample size, the
heritability estimates shrank to around 11%. More generally,
heritability estimates between studies where the sequences have
different times to their respective MRCA are not readily
compared. Studies with a more distant MRCA are likely to have
higher heritability estimates as we expect the variance of the
phenotype at the tips to increase with increasing time to the
MRCA.
Given that viral genotype is influencing viral load, the question
arises as to the source of this effect in the viral genome. The
analysis has been performed on the pol gene, where both drug
resistant and naturally occurring variation is known to affect
replicative capacity [84]. It is also possible that this between-
lineage variation (Fig. 1) could be a distal effect that may map to
one or more other genes, such as env [85], that we are detecting
through its linkage with variants in the pol gene. With increasing
availability of full-genome datasets it may be possible to address
that question directly in future.
The analysis performed here avoided issues associated with
using multiple subtypes, transmission pairs, or restricted
samples by including as many cases as possible. The aim was
to minimize bias, but this clearly would be expected to
introduce a substantial amount of noise and depends on the
availability of large datasets. In fact twenty-fold more
individuals were included than the largest previous dataset
with a significant heritability estimate [50]. Nevertheless, this
approach could allow some viral loads to be classified as set-
point when they were actually taken during the acute stage,
prior to the onset of AIDS, while on ART, or during a
transient rise in viral load. The data cleaning methods utilized
were able to exclude several cases that may have fallen into
these categories, but this was difficult when there was only one
pre-ART measure, as applied to approximately 20% of the
dataset (1,726 cases). If many of the viral loads classified as set-
point are not actually set-point measurements, this could affect
the estimate of heritability obtained. However, when the
dataset was re-run after removing these 1,726 cases, the
heritability estimates remained significant with a mean value of
7.2% (CI 3.9–10.6%), showing that any errors made in
classifying sequences with just one pre-ART viral load do not
significantly affect the estimate.
We found no evidence that subtype B HIV is becoming more
virulent in the UK. Indeed, the relatively small heritability of
around 6% implies that host, environmental, and demographic
effects play a much larger role in determining viral load than the
virus genotype in this population and suggests that any change in
viral load due to the viral genotype would be relatively small. The
implications of a heritable viral load have been extensively
explored, especially in the context of HIV adapting towards an
‘optimal’ viral load for transmission due to selection [2,81]. Our
findings, however, imply that selection on the viral genetic
component of viral load would have very limited influence on
viral evolution.
The MCMCglmm analysis estimated a small but significant
decrease over time of 20.05 log10 copies/mL/year in the mean
value of the component of viral load determined by viral
genotype (see Text S2). At this time the change due to selection
on the virus cannot be disentangled from change to due
environmental effects we have not controlled for, such as the
background level of ART in the population, so we cannot assume
all (or even any) of this change is due to selection on the viral
genome. It should also be noted that though the viral genetic
influence on viral load seems to be causing a decrease in viral
load, this does not necessarily mean that overall viral load would
be expected to decrease. As we estimate the viral genetic
contribution to the variance in viral load to be only about 6%,
changes in any of the many host and environmental factors
influencing viral load could cause viral load to remain constant or
even increase.
Previous cohort-based studies of viral load data have indeed
estimated an increase in the phenotypic value. In an analysis based
on 1,584 individuals with viral load data from the 22 CASCADE
cohorts, Dorrucci et al. [36] estimated an increase in set-point of
0.044 log10 copies/mL/year, leading to an increase in set-point
viral load of more than a log over 30 years. Herbeck et al. [37]
performed a meta-analysis based on eight previous studies
investigating change in viral load, which generated a more modest
estimate of 0.013 log10 copies/mL/year and an overall increase of
0.39 log10 copies/mL in 30 years. These changes have led to
suggestions that the virus may have evolved to become more
virulent [36,37], but this was not directly analyzed and is clearly
not the case in our study. However, a much larger fraction of the
phenotypic value of viral load in our model is determined by the
fixed effects including sex, age and time from diagnosis to first viral
load which have certainly not remained constant over the course
of the epidemic, so the two observations by no means necessarily
conflict. The studies included by Herbeck et al. range from
20.013 to 0.056 log10 copies/mL/year in their estimates, with the
largest study reporting a significant decline of 20.013 log10
copies/mL/year. This suggests that changes in viral load are
difficult to quantify and may be quite population specific, with
different environmental effects and selection pressures working in
each.
Our findings indicate that the genotype of HIV subtype B in the
UK has a small but significant effect on viral load, and suggest that
the virulence of HIV has not increased. The use of this novel
method in other situations where sequence data are available
could allow estimation of heritability where it has not previously
been possible.
Methods
8,700 initial subtype B sequences from the UK HIV RDB had
viral load measures before starting ART available from UK
CHIC. Sequences were aligned using the Stanford HIVdb
Program [86], with manual checks for high levels of ambiguity
and poor quality. To maintain both the representativeness of the
HIV epidemic in the UK and as large a sample size as possible to
improve power, a liberal definition of set-point viral load was
chosen. If multiple pre-ART viral load measures were available for
a patient, the first viral load was generally taken as the ‘set-point’
viral load. To exclude viral loads taken in AIDS, while the patient
was on unreported ART, or while the patient was still in the acute
phase of the disease, exclusion rules were applied. Unusually low
or high viral load measures (,400 copies/mL or .16106 copies/
Heritability of Set-Point Viral Load in HIV
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mL) were inspected for evidence of unreported ART use, acute
infection, or onset of AIDS, and excluded if any of these were
suggested. A full description of the rules used to discard records
and the number of records removed can be found in Table S2.
Set-point viral load values were log10 transformed before the
analysis to make the distribution approximately normal. 80% of
the patients included in our dataset had the viral load used as set-
point taken within three years of HIV diagnosis. More information
about the dates of HIV diagnosis and set-point viral load tests is
available in Text S3.
Patients with accepted viral loads and at least 840 nucleotides of
pol sequence (PR and partial RT coding regions) were analyzed. A
total of 119 identical sequences from different patients were also
removed, as they are likely to include multiple sequences from the
same individual submitted under different identifiers. This left
8,483 subtype B sequences with matched viral loads. Sequences
were stripped of codons in positions associated with drug-
resistance mutations [87,88] before phylogenetic analysis. The
analysis was repeated on sequences not stripped of resistance-
associated codons, but no significant differences in heritability
estimates were observed. To provide an unbiased root for the tree,
38 subtype reference pol sequences (subtypes A-K) from the Los
Alamos HIV Database (www.hiv.lanl.gov) were used as an
outgroup.
The large size of the dataset limited the methods available to
create the phylogenies. RAxML [65,66] is an ML-based phylo-
genetic program designed to handle large alignments and produce
accurate phylogenies by conducting a thorough topology search
[89] and also performing bootstraps. We implemented RAxML on
the Edinburgh Compute and Data Facility computer cluster. 100
bootstraps for each phylogeny were generated using the
parallelized version of RAxML on 16 processors with a run time
of 30 hrs. A comprehensive ML tree search was performed using
the threaded version of RAxML on 12 processors for an average of
100 hrs, and the bootstrap-support values were then written onto
the ML tree.
Pipeline
A new piece of software, TreeCollapseCL 4 (available at http://
hiv.bio.ed.ac.uk), was developed to aid in preparing the phylog-
enies for further analysis and investigation of the data. Using
TreeCollapseCL 4, each phylogeny was rooted and the average
length of the tree was calculated from the tips to the MRCA of the
UK sequences in the dataset (the second node from the root).
Branch length to the root was not calculated because the distance
from the root to the MRCA of the UK HIV RDB sequences can
be severely affected by the choice of outgroup used.
The sampled viral sequences and all of the internal nodes of the
phylogeny were incorporated into a genetic relatedness matrix
from which the inverse was calculated using the R [68] package
MCMCglmm [69].
The phylogenetic covariance of two individuals on a phylogeny
was assumed to be proportional to the distance between their
MRCA and the root [59]. Thus the covariance of an individual
with itself is its distance from the root in units of substitutions per
site per year. In phylogenetic comparative methods that use
ultrametric trees, the distance between the tips and the root is
often rescaled to one unit. Although the units are arbitrary, the
variance explained by the phylogeny is directly interpretable as the
variance explained in the sample of individuals used in the
analysis. However, when trees are not ultrametric, as in this case,
the root-to-tip distances vary. In this instance we standardized by
the average distance from root to tip of 0.14 substitutions per site
per year calculated earlier by TreeCollapseCL 4.
Preliminary runs were carried out on the dataset in ASReml in
order to identify the fixed effects to include in the final model. Age
at the sample date taken for set-point viral load, sex, ethnicity, time
from HIV diagnosis to the set-point viral load sample date, and
year of HIV diagnosis (as a continuous effect) were included in the
preliminary models. All of the terms were found to be highly
significant (p,0.001) and therefore all were included in the final
model. Country of origin and year of HIV diagnosis (as a
categorical effect) were also included as random effects along with
the phylogeny. Year of HIV diagnosis was included as a
continuous fixed effect to model the linear change in set-point
viral load and as a categorical random effect to account for any
random deviations around this trend from year to year. As country
of origin has many discrete levels, it was included as a random
effect in order to estimate the variance of their effects.
The significance of the effect of the phylogeny in explaining the
variance was assessed by first running the model without the
phylogeny as a ‘null’ model and then including the phylogeny. A
log-likelihood ratio test with one degree of freedom was then used
to test whether the model with the phylogeny was significantly
better at explaining the variation in viral load than the null model.
As ASReml assumes all pedigree information provided is
correct, analyses were repeated using TreeCollapseCL 4 to
collapse splits with bootstrap-support values less than 90% down
to polytomies. To further evaluate how uncertainty in the tree
could affect our heritability estimates, one hundred bootstrapped
trees were generated in RAxML and analyzed. Because of the
close phylogenetic relationship between the subtype B and D in
the pol region bootstrapped subtype D sequences can sometimes
cluster within the B clade, making it necessary to remove the
subtype D Los Alamos sequences from the phylogeny in order to
root all 100 trees by the same outgroup.
Each analysis was performed in duplicate, with the sequences
being run through RAxML and the analysis pipeline twice. The
significance threshold used was adjusted using a Bonferroni
correction for the number of replicates.
In order to investigate whether set-point viral load has changed
over time, we estimated the amount of change in viral load due to
selection. This can be estimated using Markov chain Monte Carlo
methods to calculate the total contribution of between-lineage and
within-host selection, though we cannot distinguish all change due
to within-host selection from environmental factors (see Text S2
for more detail).
In addition, to further investigate the phylogenetic effects on
viral load, a time-scaled phylogeny was produced using BEAST, a
Bayesian phylogenetic program [67]. Because the complexity of
the analysis performed by BEAST limits the number of samples
which can be run in a reasonable time-frame, a sub-sample of the
main dataset was used.
After collapsing nodes with bootstrap support values less than
90%, 965 sequences remained in un-collapsed clusters of fifteen or
more sequences. A random subsample of 652 of these sequences
was taken for analysis in BEAST. BEAST was run with a relaxed
log-normal clock and a constant population size for 100,000,000
steps, sampling every 10,000 steps. All runs were performed in
duplicate, and after 10% burn-in was removed the resulting files
were combined using an in-house script. A summary tree was then
generated using the BEAST program TreeAnnotator, and run in
ASReml to obtain heritability estimates.
Finally, in order to validate the heritability estimates produced
by our pipeline, we followed the method of Alizon et al. [50] (see
Text S1) to perform a simulation analysis where viral loads were
simulated down trees under known heritabilities.
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Figure S1 The effect of collapsing poorly-supported nodes. A
sub-section of the full RAxML tree is shown before (A) and after
(B) collapsing nodes with bootstrap support less than 90% down to
polytomies. Branch length from root to tip nodes is preserved after
collapsing.
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Figure S2 The log10 change in viral load per year due to
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environmental effects (unshaded). Though the change due to
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